Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Formato: Artigo
Lenguaje:Russo
Publicado: ABV-press 2014-11-01
Colección:Onkourologiâ
Materias:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Acceso en línea:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares